

Resource Summary Report

Generated by ASWG on Aug 9, 2026

PE/Cyanine7 anti-mouse CD3

RRID:AB_1732068

Type: Antibody

Proper Citation

BioLegend Cat# 100219, RRID:AB_1732068

Antibody Information

URL: http://antibodyregistry.org/AB_1732068

Proper Citation: BioLegend Cat# 100219, RRID:AB_1732068

Target Antigen: CD3

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE/Cyanine7 anti-mouse CD3

Description: This monoclonal targets CD3

Target Organism: mouse

Clone ID: Clone 17A2

Antibody ID: AB_1732068

Vendor: BioLegend

Catalog Number: 100219

Alternative Catalog Numbers: 100220

Record Creation Time: 20250820T003100+0000

Record Last Update: 20250820T082840+0000

Ratings and Alerts

No rating or validation information has been found for PE/Cyanine7 anti-mouse CD3.

No alerts have been found for PE/Cyanine7 anti-mouse CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 43 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Zhang Y, et al. (2026) Nociceptive neurons protect cancer cells against oxidative stress. Cell reports, 45(3), 117086.

Bilanovic J, et al. (2026) One-step generation of T-cell receptor knock-in mice in the TCR? locus. The EMBO journal, 45(12), 4321.

Zhang Y, et al. (2025) Immune targeting of triple-negative breast cancer through a clinically actionable STING agonist-CAR T cell platform. Cell reports. Medicine, 6(7), 102198.

Li J, et al. (2025) Pharmacological rescue of mutant p53 triggers spontaneous tumor regression via immune responses. Cell reports. Medicine, 6(3), 101976.

Blanchard L, et al. (2025) Fc-optimized anti-CTLA-4 antibodies increase tumor-associated high endothelial venules and sensitize refractory tumors to PD-1 blockade. Cell reports. Medicine, 6(6), 102141.

Yamashita E, et al. (2025) Red Blood Cell-Mediated Enhancement of Hematopoietic Stem Cell Functions via a Hes1-Dependent Pathway. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 39(17), e71022.

Nie X, et al. (2025) Single coadministration of erythrocyte-uricase conjugate and immunosuppressant induces durable immune tolerance for gout therapy. Science advances, 11(47), eaea5196.

Shinkawa T, et al. (2025) CD226 identifies effector CD8+ T cells during tuberculosis and costimulates recognition of Mycobacterium tuberculosis-infected macrophages. Cell reports, 44(9), 116184.

Rashidi A, et al. (2024) Myeloid cell-derived creatine in the hypoxic niche promotes glioblastoma growth. Cell metabolism, 36(1), 62.

Wang HC, et al. (2024) Kmt2c restricts G-CSF-driven HSC mobilization and granulocyte production in a methyltransferase-independent manner. Cell reports, 43(8), 114542.

Zhou C, et al. (2024) Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer. *Cancer cell*, 42(7), 1286.

Liu M, et al. (2024) The crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia. *Cancer cell*, 42(5), 885.

Ma R, et al. (2024) Vimentin modulates regulatory T cell receptor-ligand interactions at distal pole complex, leading to dysregulated host response to viral pneumonia. *Cell reports*, 43(12), 115056.

Wang S, et al. (2024) Disruption of MerTK increases the efficacy of checkpoint inhibitor by enhancing ferroptosis and immune response in hepatocellular carcinoma. *Cell reports. Medicine*, 5(2), 101415.

Shapir Itai Y, et al. (2024) Protocol for assessing murine cell doublet engagement and subsequent effects using flow cytometry and imaging flow cytometry. *STAR protocols*, 5(4), 103152.

Knorr DA, et al. (2024) Fc γ RIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment. *Cancer immunology research*, 12(3), 322.

Zhang R, et al. (2024) Hypomethylation-enhanced CRT2 expression drives malignant phenotypes and primary resistance to immunotherapy in hepatocellular carcinoma. *iScience*, 27(6), 109821.

Feng S, et al. (2024) Blockage of L2HGDH-mediated S-2HG catabolism orchestrates macrophage polarization to elicit antitumor immunity. *Cell reports*, 43(6), 114300.

Huang TY, et al. (2023) Phosphoenolpyruvate regulates the Th17 transcriptional program and inhibits autoimmunity. *Cell reports*, 42(3), 112205.

Avequin T, et al. (2023) Differential effects of sugar and fat on adipose tissue inflammation. *iScience*, 26(7), 107163.